Search Clinical Trials
Sponsor Condition of Interest |
---|
PRO1107 in Patients With Advanced Solid Tumors
Genmab
Endometrial Cancer
Ovarian Cancer
Triple Negative Breast Cancer
GastroEsophageal Cancer
Non-small Cell Lung Cancer
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety,
tolerability, PK, and antitumor activity of PRO1107 in patients with advanced solid
tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion,
and Part B: tumor specific expansion. expand
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, PK, and antitumor activity of PRO1107 in patients with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion. Type: Interventional Start Date: Jan 2024 |
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patien1
United Therapeutics
PAH
Pulmonary Hypertension
Pulmonary Arterial Hypertension
Hypertension
Connective Tissue Diseases
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of
ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or
PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1
PAH. expand
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH. Type: Interventional Start Date: Aug 2018 |
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
Hsiao-Ying Wey
Healthy
Caffeine
Adenosine
Dopamine D2/3 Receptor Availability
This research study aims to determine whether and how caffeine intake affects learning
process through reward feedback compared to placebo. The data acquired from this study
would improve our understanding on the consequence and mechanism of caffeine intake in
the aspect of learning process.
Parti1 expand
This research study aims to determine whether and how caffeine intake affects learning process through reward feedback compared to placebo. The data acquired from this study would improve our understanding on the consequence and mechanism of caffeine intake in the aspect of learning process. Participants will perform a reinforcement learning task (i.e. Probabilistic Selection Task) and a motor inhibition task (i.e. Go/NoGo task) in a brain scan. The scan will be done with the Siemens Biograph mMR positron emission tomography (PET)/ magnetic resonance imaging (MRI) 3 Tesla scanner. The PET allows us to see the changes in the "reward signals" - dopamine - in the brain using a radioactive dye called [11C]Raclopride. The MRI, on the other hand, enables us to take detailed pictures of the brain activities during cognitive tasks using a high-powered magnet. Reviewing these pictures will help us understand the influence of caffeine on reward signals and brain activities during the learning process. Type: Interventional Start Date: May 2023 |
Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)
TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics
Solid Tumor, Adult
Metastatic Breast Cancer
Advanced Breast Cancer
HER2 Mutation-Related Tumors
HER2-positive Metastatic Breast Cancer
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of
BBO-10203, a PI3Kα:RAS breaker, alone and in combination with trastuzumab in patients
with advanced solid tumors. expand
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with trastuzumab in patients with advanced solid tumors. Type: Interventional Start Date: Oct 2024 |
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Nuvalent Inc.
Locally Advanced Solid Tumor
Metastatic Solid Tumor
Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and
tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the
antitumor activity in patients with advanced or metastatic HER2-altered NSCLC.
Phase 1a dose escalation is designed to assess1 expand
Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced or metastatic HER2-altered NSCLC. Phase 1a dose escalation is designed to assess the safety and tolerability of NVL-330 and to select the candidate RP2D(s) and, if applicable, the MTD. Phase 1b expansion is designed to further evaluate the overall safety and tolerability of the candidate RP2D(s) of NVL-330 and to determine the RP2D of NVL 330 in patients with advanced or metastatic HER2 mutant NSCLC. Type: Interventional Start Date: Jul 2024 |
Assessing E-Cigarettes for Tobacco Harm Reduction in the Context of Lung Cancer Screening
Massachusetts General Hospital
Electronic Cigarette Use
Smoking, Cigarette
Nicotine Dependence
This study investigates the feasibility, acceptability, and short-term effects of
providing 4 weeks of complimentary electronic cigarettes (ECs) to 30 individuals who did
not quit after smoking cessation treatment provided in the context of lung cancer
screening and do not plan to quit smoking. Thi1 expand
This study investigates the feasibility, acceptability, and short-term effects of providing 4 weeks of complimentary electronic cigarettes (ECs) to 30 individuals who did not quit after smoking cessation treatment provided in the context of lung cancer screening and do not plan to quit smoking. This open-label single-arm pilot clinical trial will test the impact of EC provision on: 1) study feasibility, 2) EC acceptability, 3) tobacco use behavior (e.g., cigarettes per day, EC use), and 4) biomarkers (e.g., carbon monoxide, cotinine, and anabasine). Participants will be asked to switch from combustible cigarettes to the NJOY ACE 5% nicotine electronic cigarette (EC) for 4 weeks. They will be followed an additional 4 weeks after EC provision ends (to 8 weeks). The first study hypothesis is that more than 40% of eligible smokers who are offered participation in the trial will enroll, and that 75% of enrollees will complete the trial. The second study hypothesis is that participants will report fewer cigarettes smoked per day at the end of 4 weeks of EC provision, relative to their baseline values. Type: Interventional Start Date: Sep 2024 |
A Phase 1 Study of AJ1-11095 in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera M1
Ajax Therapeutics, Inc.
Primary Myelofibrosis
Post-Essential Thrombocythemia Myelofibrosis
Post-Polycythemia Vera Myelofibrosis
PMF
PPV-MF
AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label
clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK),
clinical activity and changes in biomarkers of an orally administered type II JAK2
inhibitor, AJ1-11095, in subjects with prim1 expand
AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II JAK2 inhibitor, AJ1-11095, in subjects with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor. Type: Interventional Start Date: Oct 2024 |
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Partic1
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Myeloma
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene
Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma. expand
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma. Type: Interventional Start Date: Mar 2024 |
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants1
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Sclerosis
Myasthenia Gravis
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug
levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS),
Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG). expand
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG). Type: Interventional Start Date: Mar 2024 |
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With P1
Sanofi
Dermatitis Atopic
This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind,
placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with
moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled
with topical prescription therapies1 expand
This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participants with moderate to severe AD aged 12 years and older. Study details include: At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY). For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up. For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period. The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600] (ESTUARY). Type: Interventional Start Date: Nov 2023 |
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma As a Prognostic and Response Diagnostic: LEOPARD
Dana-Farber Cancer Institute
Ewing Sarcoma
Ewing Sarcoma of Bone
Ewing Sarcoma of Soft Tissue
Peripheral Primitive Neuroectodermal Tumor
Peripheral Primitive Neuroectodermal Tumor of Bone
This is a prospective multicenter biomarker study evaluating the prognostic impact of
ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma. expand
This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma. Type: Interventional Start Date: May 2018 |
IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Lev1
Gilead Sciences
Primary Biliary Cholangitis
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in
Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance
to Ursodeoxycholic Acid (UDCA) expand
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) Type: Interventional Start Date: Sep 2023 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progr1
Bristol-Myers Squibb
Progressive Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of
BMS-986278 in Participants with Progressive Pulmonary Fibrosis. expand
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis. Type: Interventional Start Date: Oct 2023 |
REcovery from DEXmedetomidine-induced Unconsciousness
Massachusetts General Hospital
Anesthesia
Healthy
Consciousness, Level Altered
This pilot study in healthy volunteers aims to determine if biological sex has an impact
on recovery from dexmedetomidine-induced unconsciousness, and if transcranial magnetic
stimulation combined with electroencephalography (TMS-EEG) can be used to measure brain
complexity during dexmedetomidine s1 expand
This pilot study in healthy volunteers aims to determine if biological sex has an impact on recovery from dexmedetomidine-induced unconsciousness, and if transcranial magnetic stimulation combined with electroencephalography (TMS-EEG) can be used to measure brain complexity during dexmedetomidine sedation without arousing study participants. Type: Interventional Start Date: Nov 2024 |
A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy1
Jazz Pharmaceuticals
Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
The purpose of this study is to investigate behavioral and other co-occurring outcomes
with EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous
sclerosis complex (TSC) who experience seizures. expand
The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous sclerosis complex (TSC) who experience seizures. Type: Interventional Start Date: Jun 2023 |
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept)1
Pfizer
Multiple Myeloma
The main purpose of the study is to evaluate the safety and tolerability of the
combination of elranatamab and carfilzomib and dexamethasone or elranatamab and
maplirpacept.
There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of
elranatamab when given in combination w1 expand
The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optimal dose(s) of elranatamab plus maplirpacept. All study medicines are given over 4-week cycles. Everyone taking part in this study will receive elranatamab as a shot under the skin. Participants in Part 1 will also receive weekly carfilzomib as an IV infusion (given directly into a vein) and dexamethasone either by mouth (as a pill) or by IV infusion. Participants in Part 2 will receive elranatamab in combination with maplirpacept as an IV infusion (given directly into a vein) The investigators will examine the experiences of people receiving the study medicines. This will help determine if the study medicines are safe and can be used for multiple myeloma treatment. Participants will take part in this study for about 2 years after the first dose. Type: Interventional Start Date: Dec 2022 |
A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBR1
Phanes Therapeutics
Small Cell Lung Cancer (SCLC)
Large Cell Neuroendocrine Cancer (LCNEC)
Neuroendocrine Prostate Cancer (NEPC)
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Neuroendocrine Carcinomas (NEC)
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and
combination study designed to evaluate the safety, tolerability, pharmacokinetics,
pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in
combination with chemotherapy. expand
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy. Type: Interventional Start Date: Sep 2023 |
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-1
Hoffmann-La Roche
Small Cell Lung Cancer
Neuroendocrine Carcinoma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics (PD) and preliminary anti-tumor activity of RO7616789. The study will
have 3 parts: Dose Escalation (Parts 1 and 2) and Dose Expansion (Part 3). Participants
with advanced stage small cell lun1 expand
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of RO7616789. The study will have 3 parts: Dose Escalation (Parts 1 and 2) and Dose Expansion (Part 3). Participants with advanced stage small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) will be enrolled in the study. Type: Interventional Start Date: Jan 2023 |
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
Cellectis S.A.
B-cell Non-Hodgkin Lymphoma (B-NHL)
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22
administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin
Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical
activity of UCART20x22 and determine the Maximum T1 expand
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D). Type: Interventional Start Date: Nov 2022 |
Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Genmab
Platinum-Resistant Ovarian Cancer
Platinum Sensitive Ovarian Cancer (PSOC)
High Grade Epithelial Ovarian Cancer
High Grade Serous Ovarian Cancer
Primary Peritoneal Carcinoma
This study will test the safety, including side effects, and determine the
characteristics of a drug called Rina-S in participants with solid tumors.
Participants will have solid tumor cancer that has spread through the body (metastatic)
or cannot be removed with surgery (unresectable). expand
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). Type: Interventional Start Date: Dec 2022 |
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Mersana Therapeutics
HER2-positive Breast Cancer
HER2-positive Gastric Cancer
HER2-positive Non-Small Cell Lung Cancer
HER2-positive Colorectal Cancer
HER2-positive Tumors
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2. expand
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2. Type: Interventional Start Date: Jan 2023 |
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company
Breast Neoplasms
The main purpose of this study is to measure how well imlunestrant works compared to
standard hormone therapy in participants with early breast cancer that is estrogen
receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants
must have already taken endocrine therapy for1 expand
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years. Type: Interventional Start Date: Oct 2022 |
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
ALK-Abelló A/S
Peanut Allergy
This clinical research study investigates the safety, tolerability and efficacy of a
peanut SLIT-tablet in adults, adolescents, and children with peanut allergy. expand
This clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy. Type: Interventional Start Date: Sep 2022 |
MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study
Microvention-Terumo, Inc.
Intracranial Aneurysm
The objective of this study is to generate contemporaneous clinical data to facilitate a
reasonable comparison of the performance of the FRED™ X™ device with the performance of
the FRED™ device. The data generated from this study will be compared to the safety and
effectiveness of the FRED™ device1 expand
The objective of this study is to generate contemporaneous clinical data to facilitate a reasonable comparison of the performance of the FRED™ X™ device with the performance of the FRED™ device. The data generated from this study will be compared to the safety and effectiveness of the FRED™ device by meeting the same performance goals (PGs) established for the FRED™ pivotal study. Type: Interventional Start Date: Sep 2022 |
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Pat1
NRG Oncology
Metastatic Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8
Stage IV Renal Cell Cancer AJCC v8
Unresectable Renal Cell Carcinoma
This phase II trial tests whether the addition of radiation to the primary tumor,
typically given with stereotactic ablative radiation therapy (SABR), in combination with
standard of care immunotherapy improves outcomes in patients with renal cell cancer that
is not recommended for surgery and has1 expand
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer. Type: Interventional Start Date: Jun 2022 |
- Previous
- Next